{"id":"W3174532254","doi":"10.1002/hon.51_2879","title":"NIVOLUMAB PLUS BRENTUXIMAB VEDOTIN FOR RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA: EXTENDED FOLLOW‐UP FROM THE PHASE 2 CHECKMATE 436 STUDY","year":2021,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"Jewish General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Brentuximab vedotin; Medicine; Internal medicine; Nivolumab; Refractory (planetary science); Oncology; Phases of clinical research; Gastroenterology; Lymphoma; Surgery; CD30; Chemotherapy; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000497763,0.0004741059,0.00164486,0.00005374688,0.0003460562,0.00003939283,0.0002926574,0.0004511902,0.0007723502],"category_scores_gemma":[0.0007375673,0.0002947748,0.0004980491,0.0002387189,0.0001911763,0.00007500294,0.0003260119,0.0002748936,0.000203206],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001010582,"about_ca_system_score_gemma":0.001369119,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000638749,"about_ca_topic_score_gemma":0.0001486583,"domain_scores_codex":[0.9962912,0.0004962415,0.0008836468,0.001001628,0.0004872413,0.0008400059],"domain_scores_gemma":[0.9955826,0.002680964,0.0003611378,0.0007603451,0.0002627505,0.0003521325],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"nonrandomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.03414829,0.5118765,0.09550878,0.000669338,0.003791548,0.05634636,0.008169873,0.000002308062,0.006500059,0.004031371,0.1278228,0.1511327],"study_design_scores_gemma":[0.5507624,0.02309084,0.1907958,0.0002185636,0.003656542,0.002728962,0.007962977,0.0004572066,0.00798427,0.001322371,0.2100298,0.0009902662],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9845056,0.005179495,0.0002571445,0.003137891,0.001154548,0.002047747,0.0001995651,0.0001731388,0.003344872],"genre_scores_gemma":[0.9918528,0.000253471,0.001711272,0.003128171,0.000347175,0.0011198,0.0006750185,0.00004783703,0.000864486],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5166141,"threshold_uncertainty_score":0.9999504,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04112583095400109,"score_gpt":0.3361191188900827,"score_spread":0.2949932879360816,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}